Foxo Technologies (FOXO) investor relations material

Executive summary

• Net revenues for Q2 2026 were $4.7M, down 10% year-over-year, while six-month revenues rose 18% to $9.9M, driven by growth in Healthcare and the addition of Life Science Services from the Vector acquisition.

• Net income attributable to common stockholders was $8.0M for Q2 2026 and $6.6M for the first half, both reflecting a $9.1M non-cash gain from the forfeiture of unvested management shares; excluding this, the company posted operating losses.

• The company completed a major restructuring of Series A Preferred Stock, exchanging $7.8M of preferred shares for senior unsecured notes, and entered a strategic technology license agreement for its epigenetics IP.

Financial highlights

• Q2 2026 net revenues: $4.7M (down from $5.2M in Q2 2025); six-month revenues: $9.9M (up from $8.4M in 2025).

• Q2 2026 net income: $8.1M (vs. $-0.5M in Q2 2025); six-month net income: $6.7M (vs. $-1.1M in 2025), both driven by a $9.1M non-cash reversal.

• Adjusted EBITDA for Q2 2026 was $(0.5)M, and for the first half $(1.2)M, reflecting ongoing operating losses when excluding non-recurring items.

• Cash used in operations for the first half was $0.3M, with cash on hand at $58K and a working capital deficit of $35.9M as of June 30, 2026.

Outlook and guidance

• Management expects continued operating losses and negative cash flow, with additional capital required to fund operations and execute growth strategies.

• The company is pursuing further acquisitions, including a pending $3.5M asset purchase in the blood collection sector, contingent on new financing.